Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CDC7 | O00311 | 10/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513312 | 1.00 | HSD17B10 (0.49) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL29693859 | 0.85 | HSD17B10 (0.63) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL22905056 | 0.85 | HSD17B10 (0.63) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL22909082 | 0.84 | STING1 (0.49) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL22908994 | 0.81 | HSD17B10 (0.49) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL30765125 | 0.81 | HSD17B10 (0.49) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL29513181 | 0.78 | ALDH1A1 (0.51) | HSD17B10KDM4ELMNAALDH1A1HTT | |
| SCHEMBL22909058 | 0.78 | ALDH1A1 (0.51) | HSD17B10KDM4ELMNAALDH1A1HTT | |
| SCHEMBL22904903 | 0.77 | HSD17B10 (0.47) | HSD17B10CDC7DBF4KDM4ELMNA | |
| SCHEMBL29443064 | 0.77 | HSD17B10 (0.47) | HSD17B10CDC7DBF4KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD. (AU) | 2025-08-12 | — | — | US | disclosed |
| EP-3999185-B1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD (AU) | 2023-08-30 | — | — | EP | disclosed |
| EP-3999185-B1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD (AU) | 2023-08-30 | — | — | EP | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| EP-3999185-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT Pty Limited (AU) | 2022-05-25 | — | — | EP | disclosed |
| CN-114206882-A | Benzothiophene, thienopyridine, and thienopyrimidine derivatives for modulation of STING | CTXT私人有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021009365-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LIMITED (AU) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021009365-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LIMITED (AU) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, MAVS | HSD17B10 4526/4885CDC7 2787/4885DBF4 175/4885 |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | STING1, CGAS, MAVS | HSD17B10 4526/4885CDC7 2787/4885DBF4 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.